Zobrazeno 1 - 5
of 5
pro vyhledávání: '"C Fontela Bulnes"'
Autor:
B Fernández García, C Fontela Bulnes, M Ercilla Liceaga, A Eceiza Díez, I Beristain Aramendi, A Ros Olaso, J Boo Rodriguez, T Gonzalez Fernández, B Odriozola Cincunegui, L Mendarte Barrenechea, MP Bachiller Cacho
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0547893d342132feeac555886b27a2c8
https://doi.org/10.1136/ejhpharm-2022-eahp.338
https://doi.org/10.1136/ejhpharm-2022-eahp.338
Autor:
N Alzueta Isturiz, P Aldaz Herce, A Gil Setas, C Fontela Bulnes, A Echeverría Gorriti, J Garjón Parra
Publikováno v:
Anales del sistema sanitario de Navarra. 43(3)
espanolFundamento. El objetivo de este estudio fue evaluar la implementacion de un programa piloto de optimizacion de antimicrobianos (PROA) en equipos de Atencion Primaria (EAP) en Navarra. Material y metodos. Estudio experimental, no aleatorizado,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ebb3da1cfb10c9b0f549993c0ca8a7e
https://pubmed.ncbi.nlm.nih.gov/33057243
https://pubmed.ncbi.nlm.nih.gov/33057243
Autor:
R de la Riva Bohigas, M Gracia Ruiz de Alda, M. Rivero Marcotegui, C Fontela Bulnes, A Muñoz San Juan, J Repáraz Padrós, J Polo García, J Preciado Goldaracena, J Alfaro Basarte, R Juanbeltz Zurbano
Publikováno v:
Drug information and pharmacotherapy.
Background Dolutegravir/abacavir/lamivudine (Triumeq) is a new oral drug to treat human immunodeficiency virus (HIV) offering a single pill regimen. Treatment discontinuations due to adverse events occurred in our clinical experience raising concerns
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::471e36d2d228b7a7140b36583aa2ca45
https://doi.org/10.1136/ejhpharm-2017-000640.293
https://doi.org/10.1136/ejhpharm-2017-000640.293
Autor:
M Coma Punset, C Fontela Bulnes, J Preciado Goldaracena, J Fernández González, N Larrea Goñi, R Juanbeltz Zurbano, J Polo García, JI Yanguas Bayona, R San Miguel Elcano, J Alfaro Basarte
Publikováno v:
Clinical pharmacy.
Background Biological agents targeting interleukin such as ustekinumab and secukinumab are strategies employed in psoriasis treatment. Ustekinumab requires double doses in patients over 100 kg, which implies an increase in costs due to the absence of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7cc26920839b388b1821258aa2373c66
https://doi.org/10.1136/ejhpharm-2017-000640.114
https://doi.org/10.1136/ejhpharm-2017-000640.114
Autor:
José Otero, María, Pérez-Encinas, Montserrat, Tortajada-Goitia, Begoña, Manuel Rodríguez-Camacho, Juan, Plata Paniagua, Sergio, José Fernández-Megía, María, Esteban Cartelle, Helena, Manuel Caro-Teller, José
Publikováno v:
Farmacia Hospitalaria (1130-6343); Nov/Dec2023, Vol. 47 Issue 6, pT268-T276, 9p